All In Biotech

Drug Trial Radar · NCT05831449

CPL-01 in the Management of Postoperative Pain After Bunionectomy

A Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Efficacy and Safety of CPL-01 in the Management of Postoperative Pain After Unilateral Distal First Metatarsal Bunionectomy With Osteotomy

Last checked: Nov 19, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 616 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

616

Actual

Start

May 22, 2023

Primary completion

Sep 25, 2025

Study completion Oct 6, 2025

Sponsor

Lead sponsor
Cali Pharmaceuticals LLCIndustry
Sponsor type
Industry
First posted
Apr 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Subjects receive study drug during bunionectomy and are followed for pain and opioid use, with the hypothesis that those who receive CPL-01 will have less pain and less opioid use than either control arm.

Conditions

  • Bunion
  • Post-operative Pain

Interventions

  • Local anesthetic injection of CPL-01Drug

    Local anesthetic injection (CPL-01)

  • Naropin, 0.5% Injectable SolutionDrug

    Local anesthetic injection (positive control \[Naropin\])

  • PlaceboDrug

    Local anesthetic injection (negative control \[saline placebo\])

  • Morphine rescue medicationDrug

    Rescue opioid (IV morphine) allowed if requested

  • Acetaminophen rescue medicationDrug

    Rescue non-opioid (oral acetaminophen) allowed if requested

  • Oxycodone rescue medicationDrug

    Rescue opioid (PO oxycodone) allowed if requested

  • BunionectomyProcedure

    Operative bunion repair

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative Pain ScoreTime frame: 72 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Todd Bertoch

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.